Common TitleASPIRE
Official Title Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure (ASPIRE)
Phase Phase III
ClinicalTrials.gov NCT02263326
Treatments
Lamivudine
, Lamivudine
Tradename:EpivirOther Names:3TCClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)Dolutegravir-Lamivudine
Dolutegravir-Lamivudine
Tradename:DovatoOther Names:DTG-3TCClass:Single-Tablet RegimensCategories Treatment-ExperiencedDual Therapy
Funding
IndustryViiV Healthcare
References
- Li JZ, Sax PE, Marconi VC, et al. No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial. Open Forum Infect Dis. 2019;6:ofz056.
- Taiwo BO, Marconi VC, Berzins B, et al. Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial. Clin Infect Dis. 2018;66:1794-7.